Genomic Health Announces Results from Six Studies Demonstrating Unique Value of the Oncotype DX Breast Cancer Test in Early Stage Breast Cancer

REDWOOD CITY, Calif., Dec. 10, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results from six studies of the Oncotype® DX breast cancer test presented at the 34^th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reinforcing the impact of the test on facilitating better informed treatment decisions in patients with node-negative and node-positive invasive early-stage breast cancer.  Additionally, two studies demonstrated the test's cost effectiveness in invasive breast cancer and ductal carcinoma in situ (DCIS), adding to the large body of evidence of Oncotype DX's economic value across various healthcare systems. 

"Our extensive body of clinical evidence showcases the ability of Oncotype DX to play a critical role in breast cancer treatment, while providing a positive impact on health systems worldwide at this time when societies are seeking value from their healthcare spending," said Steven Shak, M.D., chief medical officer and executive vice president for research and development at Genomic Health.  "With our knowledge of the human genome, the ability to sequence vast amounts of data using next generation technology and our proven ability to translate this into actionable information, we believe we are positioned to lead the delivery of new genomic tests that improve patient outcomes throughout their cancer journey."

Studies Continue to Reinforce Oncotype DX Provides Important Individualized Information That Can Not Be Revealed by Traditional Measures Alone

"Personalized medicine requires accurate, individualized assessment of the patient's tumor biology to enable better informed treatment decisions," said Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP).  "Oncotype DX is the only clinically validated multi-gene assay that gives a quantitative assessment of the risk of distant recurrence and has been proven to predict chemotherapy treatment benefit. The importance of understanding the continuous tumor biology is paramount to making the right treatment decisions for each individual patient."

New Data Reinforced Cost-Effectiveness of Oncotype DX Use in Patients with Invasive Early Stage Breast Cancer and DCIS 

• Results from the third Oncotype DX health economics analysis of the Recurrence Score result in early-stage, estrogen receptor-positive, node-negative, patients in Japan demonstrated that chemotherapy use decreased by 19 percent with use of the test and was projected to be cost-effective in the region (Abstract: P5-15-06). 
• Additionally, a cost-effectiveness analysis of the Oncotype DX DCIS Score® compared to standard clinical assessment indicated that the use of the DCIS Score was more cost-effective than traditional clinical assessment (Abstract: P5-15-01).

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.  The company's lead product, the Oncotype DX^® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of September 30, 2012, more than 10,000 physicians in over 65 countries had ordered more than 320,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org. 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that it is positioned to lead the delivery of new genomic tests that improve patient outcomes; the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the demand for the company's tests; and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.  

SOURCE Genomic Health, Inc.